338 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (338)
- Addiction (4)
- Allergy, Asthma, & Immunology (1)
- Autoimmune Disorders (2)
- Blood Disorders (2)
- Bone & Muscle (2)
- Cancer (93)
- COVID-19 (Coronavirus) (8)
- Diabetes (6)
- Ear, Nose and Throat (6)
- Endocrine & Metabolic Disease (1)
- Gastrointestinal and Digestive Diseases (6)
- Hair and Skin Disorders (1)
- Healthy Volunteers (47)
- Heart Disease (23)
- Infectious Disease (11)
- Liver Disease (13)
- Lung Disease (2)
- Neurological Disorders (46)
- Obesity (7)
- Obstetrics & Gynecology (12)
- Pediatrics (22)
- Psychiatric Disorders (4)
- Rehabilitation (1)
- Stroke (2)
- Transplant (15)
- Vascular Conditions (1)
Displaying 1 - 12 of 12
Condition: Cancer / Multiple Myeloma
Investigator: Rajshekhar Chakraborty, MD
Status: Currently Recruiting
The purpose of the study is to determine the proportion of patients with lowest minimal residual disease (MRD) response obtainable after receiving 6 cycles of study treatment. Minimal residual disease is multiple myeloma cells below the level of 1 cancer cell out of 100,000 in the bone marrow. For patients who are MRD "positive" at the end of 6…
Condition: Cancer / Gynecologic Cancer
Investigator: Jason Wright, MD
Status: Currently Recruiting
The purpose of this study is to collect and store donated blood samples and associated medical data from participating subjects to help develop an ovarian cancer blood test and for potential research into other gynecological diseases.
Condition: Cancer / Gynecologic Cancer
Investigator: Jason Wright, MD
Status: Currently Recruiting
The purpose of this research study is to learn if sacituzumab govitecan (also called SG) can improve lifespan and delay the growth or spread of the disease in participants with endometrial cancer when compared to chemotherapy (doxorubicin or paclitaxel). Sacituzumab govitecan is a type of drug called an antibody-drug conjugate. An antibody-drug conjugate (…
Condition: Cancer / Gynecologic Cancer
Investigator: Jason Wright, MD
Status: Currently Recruiting
The purpose of the study is to compare how well Rina-S works against ovarian cancer, primary peritoneal cancer, or fallopian tube cancer compared to chemotherapy drugs that are already approved and used for your type of cancer. You have an equal (50:50) chance of getting Rina-S or an approved chemotherapy agent as treatment in this study. Rina-S is not…
Condition: Cancer / Gynecologic Cancer
Investigator: Jason Wright, MD
Status: Currently Recruiting
The purpose of this clinical research study is to develop a sample collection method that is less invasive than current endometrial sampling methods (uterine sample collection) and develop a diagnostic test from these samples which is as informative in diagnosing the absence of endometrial (uterine) cancer as currently available methods.
Condition: Cancer / Gynecologic Cancer
Investigator: Jason Wright, MD
Status: Currently Recruiting
The goal of this clinical research study is to compare the outcomes of minimally invasive surgery (the investigational surgery) to laparotomy (the current standard of care) in women with Epithelial Ovarian Cancer (EOC) who receive chemotherapy before and after surgery. Researchers want to learn if one surgery can prevent the disease from returning for…
Study of Daratumumab in Addition to Chemotherapy for Patients with Smoldering Multiple Myeloma (SMM)
Condition: Cancer / Multiple Myeloma
Investigator: Rajshekhar Chakraborty, MD
Status: Currently Recruiting
The purpose of this study is to determine whether patients with high-risk smoldering multiple myeloma when treated with daratumumab in addition to lenalidomide and dexamethasone live longer when compared to patients with high-risk smoldering multiple myeloma patients treated with lenalidomide and dexamethasone. We would also like to know whether the period…
Condition: Cancer / Gynecologic Cancer
Investigator: June Hou, MD
Status: Currently Recruiting
The main purpose of this study is to learn about the safety of REGN4018 and to find out what dose of REGN4018 can be given alone or in combination with cemiplimab to research subjects with ovarian cancer without too many side effects. The study will also look at the levels of REGN4018 and/or cemiplimab in the body and measure how well your body can remove…
Condition: Cancer / Multiple Myeloma
Investigator: Rajshekhar Chakraborty, MD
Status: Currently Recruiting
This study is looking at people who have recently been newly diagnosed with a type of cancer called multiple myeloma (NDMM). The purpose of this study is to learn about the safety, tolerability (how your body reacts to the study drug), and effectiveness (tumor shrinkage) of linvoseltamab (called study drug) in participants with NDMM as a first step in…
Condition: Cancer / Multiple Myeloma
Investigator: Divaya Bhutani, MD
Status: Currently Recruiting
The purpose of this study is to test whether BMS-986393 in combination with other anti-cancer drugs is safe and effective at treating people with multiple myeloma (MM) that has come back after previous treatment (relapsed) or is not responding to current treatment (refractory). The researchers think that the combinations of alnuctamab, mezigdomide, or…
Condition: Cancer / Multiple Myeloma
Investigator: Rajshekhar Chakraborty, MD
Status: Currently Recruiting
This study is the first time REGN5458 will be combined with other cancer therapies. The main goal is to understand if REGN5458 can be given safely with other cancer study treatments, and if so, what dose of REGN5458 should be used for each combination. The investigational drug, REGN5458, is not approved by the Food and Drug Administration (FDA).
Condition: Cancer / Multiple Myeloma
Investigator: Rajshekhar Chakraborty, MD
Status: Currently Recruiting
The purpose of this study is assess the safety, safest dose, and effectiveness of venetoclax in combination with dexamethasone in subjects with t(11;14) positive relapsed (comes back) or refractory (did not get better) light chain amyloidosis. Furthermore, the purpose of phase 2 part of this study is to compare the effectiveness of venetoclax and…
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website,
you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the
Columbia University Website Cookie Notice.
I AGREE